Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.

@article{Hatano2013ResidualPC,
  title={Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.},
  author={Koji Hatano and Souhei Yamaguchi and Keisuke Nimura and Kouki Murakami and Akira Nagahara and Kazutoshi Fujita and Motohide Uemura and Yasutomo Nakai and Mutsumi Tsuchiya and Masashi Nakayama and Norio Nonomura and Yasufumi Kaneda},
  journal={Molecular cancer research : MCR},
  year={2013},
  volume={11 9},
  pages={
          1088-100
        }
}
UNLABELLED Despite an increasing prevalence of patients with docetaxel-refractory prostate cancer, little is known about the tumor biology of the docetaxel-resistant residual tumor cells compared with primary tumor cells. In this study, tumorigenic potential was increased in the docetaxel-resistant residual prostate cancer cell lines (DRD, 1G7 and PC3DR) compared with parental cells (DU145 or PC3). Enhanced tumorigenic potential was conferred by oncogenic c-Myc, which was stabilized by… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations